Conference Call with Natco Pharma Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Natco Pharma announced Q3FY25 results NATCO recorded consolidated total revenue of Rs 651.1 crore for Q3FY25, as against Rs 795.6 crore for Q3FY24. The net profit for the period, on a consolidated basis, was Rs 132.4 crore as against Rs 212.7 crore for Q3FY24. The Board of Directors has declared third interim dividend of Rs 1.5 per equity share, for FY25. Result PDF